共 50 条
- [1] LOTIS-5, an Ongoing, Phase 3, Randomized Study of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCLCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S473 - S474Kwiatek, Michal T.Carlo-Stella, CarmeloUrban, AndrzejNiewiarowski, AndrewWang, LuqiangLaughlin, MaryHamadani, Mehdi
- [2] Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Hamadani, MehdiLinhares, YuliyaGandhi, MitulChung, MichaelAdamis, HelenaUngar, DavidCarlo-Stella, CarmeloKingsley, EdDepaus, JulienSnauwaert, SylviaKwiatek, MichalLopez-Jimenez, Javier
- [3] Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCLCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S372 - S372Kingsley, EdwinGrosicki, SebastianKwiatek, MichalSalar, AntonioSnauwaert, SylviaWang, YingAdamis, HelenaWang, LuqiangDepaus, Julien
- [4] Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCLCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S439 - S440Kwiatek, MichalGrosicki, SebastianLopez Jimenez, JavierPinzon Marino, Sergio FelipeSnauwaert, SylviaKingsley, EdwinZacchetti, GiovannaWang, YingWang, LuqiangDepaus, Julien
- [5] Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Hamadani, MehdiLinhares, YuliyaGandhi, MitulChung, MichaelAdamis, HelenaUngar, DavidCarlo-Stella, Carmelo
- [6] A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)BLOOD, 2022, 140 : 6638 - 6639Westin, JasonBurke, John M.Chapman, Andrew E.Kilavuz, TurkXu, CindySchmuely, YochiStanford, Brad LaneBeedle, EmilyRadford, John
- [7] A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-Cell Lymphoma (LOTIS-9)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S368 - S368Westin, JasonBurke, John M.Chapman, Andrew E.Kilavuz, TurkXu, CindyShmuely, YochiRadford, John
- [8] Incidence, Onset, and Management of Edema and Effusion in Patients Treated with Loncastuximab Tesirine for R/R DLBCL in the LOTIS Clinical Trial ProgramCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S397 - S398Alderuccio, Juan PabloArdeshna, KiritHess, BrianRadford, JohnLunning, MattUngar, DavidBurke, MuneetWang, LuqiangSolh, Melhem
- [9] ONSET, DURATION, AND MANAGEMENT OF EDEMA AND EFFUSION IN PATIENTS TREATED WITH LONCASTUXIMAB TESIRINE FOR R/R DLBCL: UPDATED RESULTS FROM THE LOTIS-2 CLINICAL TRIALONCOLOGY NURSING FORUM, 2022, 49 (02) : E56 - E56Grandas, ClaudiaHendrickson, LindseyAlderuccio, Juan PabloHess, BrianUngar, DavidSolh, Melhem
- [10] Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Sehn, Laurie HelenKamdar, ManaliHerrera, Alex FranciscoMcMillan, AndrewFlowers, ChristopherKim, Won SeogKim, Tae MinOzcan, MuhitDemeter, JuditHertzberg, MarkTrneny, MarekSalles, Gilles A.Davies, AndrewHirata, Jamie H.Cheng, JiKu, GraceMatasar, Matthew J.